

AT CENTRAL OUTREACH WELLNESS CENTER

We believe patients should have an active role in making an informed care decision regarding your HIV prevention.

Please review this information to discuss with your healthcare provider.



“Our mission is to promote wellness in our community by fostering our patients’ whole selves. Our focus is on culturally competent care by striving to understand our client’s needs and treat them holistically.”

Pennsylvania

Aliquippa
2360 Hospital Drive
Upper Suite 1, Aliquippa, PA
Phone: (724) 707-1155
Fax: (202) 838-0396

Erie
3104 State St
Erie, PA
Phone: (814) 454-0000
Fax: (814) 699-9400

Pittsburgh
127 Anderson Street
Suite 101, Pittsburgh, PA
Phone: (412) 322-4151
Fax: (844) 389-8800

Washington
817 Jefferson Ave
Washington, PA
Phone: (724) 993-8000
Fax: (418) 431-0146

Ohio

Cleveland
2323 Lee Road,
Cleveland Heights, OH
Phone: (216) 350-1000
Fax: 844-389-1405

Columbus
2680 W Broad St.,
Columbus, OH
Phone: (614) 360-2900
Fax: 844-389-1405

www.CentralOutreach.com



PrEP Choices

Patient Options Guide



CENTRAL OUTREACH

WELLNESS CENTER

Call (412) 844-PrEP
to discuss starting PrEP today!

F&CK WITHOUT FEAR

PrEP

PrEP Overview:

You have multiple options for HIV prevention treatment. Common risk factors and concerns are shared by all types of PrEP like nausea, headaches, vomiting, rash, and lack of appetite.

- All PrEP options are 92-99% effective in preventing HIV infection
- Requires routine appointments at 2 or 3 month intervals
- At Central Outreach partnered pharmacies, you can expect **Zero Out-of-Pocket** expenses for your PrEP medication (Lab costs not included, state-funded testing available for qualified patients).
- Recommended STI screening is performed as well as annual Hepatitis and Cholesterol testing
- Taking Prep routinely is important to minimize your risk of contracting treatment-resistant HIV

For additional information on PrEP visit: www.cdc.gov/HIV/basics/prep

ORAL PREP

There are two options for oral PrEP:

- **Truvada**—was originally approved for daily oral PrEP in 2012
- **Descovy**—Approved in 2019 as alternative HIV prevention option. Not currently approved for persons assigned female at birth.

Both require a daily oral dose and 3-month follow-up appointments.

Having infrequent or planned anal sex?

See our **“Taking PrEP 2-1-1 for Anal Sex” pamphlet.**



	<u>Concerns</u>
Truvada	Kidney Damage Risk, Bone Density Loss
Descovy	Increased Cholesterol, Weight Gain ~5%


INJECTABLE PREP

Approved in 2021, Apretude (cabotegravir 200 mg/ml) is a long-acting HIV prevention option.

- Optional 28 day oral lead-in for tolerance assessment.
- Initial injection lasts 1 month. Following doses provide 2 months of protection

Apretude Concerns

- Increased risk of developing treatment-resistant HIV if stopped without oral PrEP.
- Injection site pain, swelling or bruising



For a complete overview of side effects, risks, or concerns ask your clinician.